SPONSOR
Shanghai Changzheng Hospital
Total Trials
8
Recruiting
8
Phases
EARLY_Phase 1, Phase 2
Conditions studied: Brittle Type 1 Diabetes MellitusMetastatic Colorectal Cancer (mCRC)Prostate CancerThyroid Associated OphthalmopathyRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell LeukemiaMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate CancerIntrahepatic CholangiocarcinomaAdvanced Colorectal Cancer in the Third-line Treatment and Beyond
NCT06196996
Recruiting
Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus
Brittle Type 1 Diabetes Mellitus
NCT06621173 EARLY_Phase 1
Recruiting
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC Patients
Metastatic Colorectal Cancer (mCRC)
NCT06509919
Recruiting
Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer
Prostate Cancer
NCT06590220
Recruiting
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
Thyroid Associated Ophthalmopathy
NCT06718270 EARLY_Phase 1
Recruiting
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple Myeloma
NCT06228404 EARLY_Phase 1
Recruiting
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Metastatic Castration-resistant Prostate Cancer
NCT06583993 EARLY_Phase 1
Recruiting
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients
Intrahepatic Cholangiocarcinoma
NCT06930118 Phase 2
Recruiting
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Advanced Colorectal Cancer in the Third-line Treatment and Beyond